CORD-19:932bcdd2f6c6d487386e8bf983e4874387771be1 / 253014-253154 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T28222","span":{"begin":0,"end":140},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Results: CD200Fc (that signals the CD200R) suppressed clinical disease when administered during both the priming and effector stages of EAE."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T118","span":{"begin":0,"end":140},"obj":"Sentence"}],"text":"Results: CD200Fc (that signals the CD200R) suppressed clinical disease when administered during both the priming and effector stages of EAE."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T389","span":{"begin":136,"end":139},"obj":"Phenotype"}],"attributes":[{"id":"A389","pred":"hp_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/HP_0002383"}],"text":"Results: CD200Fc (that signals the CD200R) suppressed clinical disease when administered during both the priming and effector stages of EAE."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1308","span":{"begin":136,"end":139},"obj":"Disease"},{"id":"T1281","span":{"begin":136,"end":139},"obj":"Disease"}],"attributes":[{"id":"A1308","pred":"mondo_id","subj":"T1308","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A1309","pred":"mondo_id","subj":"T1308","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A1310","pred":"mondo_id","subj":"T1308","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A41703","pred":"mondo_id","subj":"T1281","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A82060","pred":"mondo_id","subj":"T1281","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A9070","pred":"mondo_id","subj":"T1281","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"}],"text":"Results: CD200Fc (that signals the CD200R) suppressed clinical disease when administered during both the priming and effector stages of EAE."}